Pharmacokinetics and biotransformation investigation in beagle dog of active compounds from naoxintong capsule - 19/12/20
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 7 |
| Iconographies | 4 |
| Vidéos | 0 |
| Autres | 0 |
Graphical abstract |
Highlights |
• | Identify prototype and catabolites of Naoxintong Capsules (NXTC) in beagle dog plasma. |
• | Characterize crucial in vivo biotransformation pathways of absorbed constituents of NXTC. |
• | Pharmacokinetics of six key components of NXTC. |
Abstract |
Naoxintong Capsule (NXTC), a standardized herbal medicine, has been widely applied in treating cardiovascular and cerebrovascular diseases with remarkable efficacy. However, the efficacy contributing components of NXTC are unclear, and the in vivo absorption and metabolism processes of NXTC remain largely obscured. In this study, using beagle dog as model species, we have identified and tentatively characterized 25 prototype and 15 catabolites of NXTC in beagle dog plasma by ultra-fast liquid chromatography/quadrupole-time-of-flight tandem mass spectrometry (UFLC-Q-TOF-MS/MS). We have proposed the in vivo bio-transformation pathways of these absorbed constituents. In addition, for six crucial components, we have developed a quantitative method and conducted plasma pharmacokinetic study of these six components by rapid resolution liquid chromatography tandem triple quadrupole mass spectrometry (RRLC-QQQ-MS/MS). In conclude, our study provided comprehensive insights into the understanding of the plasma absorbed components profiling of NXTC as well as their in vivo transformation behaviors, which would be of great value for identifying efficacy contributing critical components as well as mechanism related investigations of NXTC in the future.
Le texte complet de cet article est disponible en PDF.Abbreviations : ADME, AUC, CFDA, NXTC, RRLC-QQQ-MS/MS, RSD, TCM, t1/2, UFLC-Q-TOF-MS/MS
Keywords : Naoxintong capsule, Plasma metabolite, Pharmacokinetics, LC–MS/MS, UFLC-Q-TOF-MS/MS
Plan
Vol 133
Article 110940- janvier 2021 Retour au numéro
Article précédent
- Long-term treatment of polysaccharides-based hydrogel microparticles as oral insulin delivery in streptozotocin-induced type 2 diabetic mice
- Yu Yang, Shengqin Chen, Yang Liu, Yingbei Huang, Kit-Leong Cheong, Bo Teng, Wenhua Liu
- Interactions of the major effective components in Shengmai formula with breast cancer resistance protein at the cellular and vesicular levels
- Lingna Wu, Jianming Liu, Jinxia Hou, Tao Zhan, Li Yuan, Fanglan Liu, Yuqing Xiong, Jinfang Hu, Chunhua Xia
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?